转移性去势抵抗性前列腺癌患者中[177Lu]Lu-PSMA I&T与[177Lu]Lu-PSMA-617的配对分析
该配对分析纳入两个中心的110例转移性去势抵抗性前列腺癌患者,55例接受[177Lu]Lu-PSMA I&T,55例匹配接受[177Lu]Lu-PSMA-617。两组临床相关毒性均较低,[177Lu]Lu-PSMA I&T组中位OS为12个月,[177Lu]Lu-PSMA-617组为13个月,差异无统计学意义(P=0.89)。
要点
- 两组临床相关毒性均较低,III级贫血在I&T组为1.8%,在617组为9.1%。
- [177Lu]Lu-PSMA I&T组中位OS为12个月,[177Lu]Lu-PSMA-617组为13个月,差异无统计学意义(P=0.89)。
- 匹配标准包括首次周期年龄、Gleason评分、PSA值和既往紫杉烷类化疗。
核心结论
- 在两种最常用于PSMA放射性配体治疗的药物配对分析中,两种化合物的临床相关毒性发生率均较低,且未观察到OS的相关差异。
研究设计与样本
- 配对分析纳入两个中心的110例转移性去势抵抗性前列腺癌患者,55例接受[177Lu]Lu-PSMA I&T,55例匹配接受[177Lu]Lu-PSMA-617。
- 匹配标准包括首次周期年龄、Gleason评分、前列腺特异性抗原(PSA)值和既往紫杉烷类化疗。
- 采用常见不良事件术语标准(CTCAE v. 5.0)评估毒性特征,包括骨髓和肾脏毒性,并比较两组总生存(OS)。
主要发现
- III级贫血在[177Lu]Lu-PSMA I&T组为1例(1.8%),在[177Lu]Lu-PSMA-617组为5例(9.1%)。
- [177Lu]Lu-PSMA-617组记录到1例(1.9%)III级血小板减少。
- 除此之外,未出现其他III/IV级毒性。
- [177Lu]Lu-PSMA I&T组中位OS为12个月,[177Lu]Lu-PSMA-617组中位OS为13个月,差异无统计学意义(P=0.89)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Labelled with lutetium-177, the urea-based small molecules PSMA I&T and PSMA-617 are the two agents most frequently used for radioligand therapy (RLT) in patients with advanced metastatic castration-resistant and prostate-specific membrane antigen (PSMA) expressing prostate cancer (mCRPC). In this matched-pair analysis, we aimed to compare the toxicity and efficacy of both agents for PSMA-directed RLT. MATERIALS AND METHODS: A total of 110 mCRPC patients from two centres were accrued, 55 individuals treated with [177Lu]Lu-PSMA I&T, and a matched cohort of 55 patients treated with [177Lu]Lu-PSMA-617. Matching criteria included age at the first cycle, Gleason score, prostate-specific antigen (PSA) values, and previous taxane-based chemotherapy. Using common terminology criteria for adverse events (CTCAE v. 5.0), toxicity profiles were investigated (including bone marrow and renal toxicity). Overall survival (OS) between both groups was compared. RESULTS: Toxicity assessment revealed grade III anaemia in a single patient (1.8%) for [177Lu]Lu-PSMA I&T and five (9.1%) for [177Lu]Lu-PSMA-617. In addition, one (1.9%) grade III thrombopenia for [177Lu]Lu-PSMA-617 was recorded. Apart from that, no other grade III/IV toxicities were present. A median OS of 12 months for patients treated with [177Lu]Lu-PSMA I&T did not differ significantly when compared to patients treated with [177Lu]Lu-PSMA-617 (median OS, 13 months; P = 0.89). CONCLUSION: In this matched-pair analysis of patients receiving one of the two agents most frequently applied for PSMA RLT, the rate of clinically relevant toxicities was low for both compounds. In addition, no relevant differences for OS were observed.
引用
- Hartrampf PE, Weinzierl FX, Buck AK, et al. Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022. PMID: 35243517. doi:10.1007/s00259-022-05744-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。